Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… carried out at the Chemical Biology Laboratory of the Department of Medicines and Health Technologies (MTS - Univ. … funding the following month. In June 2025, the start-up was selected by Bpifrance to join the deep tech community. DETERA was also a finalist for the IPSEN Golden Ticket. The three …
Published on: